By Leitat
We offer a complete set of services to boost the development of new drugs and vaccines in the pharmaceutical and veterinary sectors. From the generation and characterization of monoclonal antibodies to validation, our experts are with you at every stage of the process. Our expertise in advanced technologies, such as bioprinting and in vivo imaging, allows us to offer customized solutions and accelerate time to market. Services at your fingertips: Hybridoma and phage display technologies for obtaining full-length monoclonal antibodies or antibody fragments of different species (scFvs and VHHs) with applications in therapy and diagnosis. We cover the entire value chain in the generation of new biological entities, from conception and development to antibody production and purification. Antibody engineering: isotype changes, species changes, CDR grafting, chimerization, fragment expression. Non-regulatory preclinical validation (in vitro/in vivo) of new molecular entities (NMEs) in oncology, neurodegenerative diseases, immune-mediated inflammatory diseases, dermatology/dermocosmetics, musculoskeletal disorders and fibrotic processes. Organs on chip and microphysiological systems and biomechanical/biochemical stimulation for drug evaluations, disease modeling, toxicity testing, and tissue or organ interaction studies. Discovery and validation of biomarkers in biofluids (blood, plasma/serum, saliva, urine, tears…). Analysis of the humoral and cellular inflammatory response. Comprehensive solutions for microbiome studies: in vitro, in vivo models and metagenomics studies. Bioprinting and engineering tissues of custom models as drug testing platforms, and the creation of biocompatible implants. Obtaining tools and tests for the validation and quality control of vaccines in human or veterinary health. In vitro and in vivo exploratory toxicology studies (non-GLP)
